Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

The company now expects full-year sales growth of 8% to 14% at a constant exchange rate, down from its previous estimate of ...

Novo Nordisk A/S named its head of international operations as chief executive officer after slumping weight-loss drug sales led to a profit warning that wiped $93 billion off its market value.

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...